CEO Executive AssistantRegulatory compliance in the pharmaceutical industry is not optional, selective, or subject to commercial convenience. It is a foundational organizational obligation with direct implications for patient safety, product approval, commercial viability, and the CEO’s personal legal exposure. These stakes make regulatory compliance one of the domains where pharma CEOs most resist delegation, reasoning that if the consequences are this serious, the CEO must stay closely involved.
This reasoning contains a valid insight (the stakes are real) but leads to the wrong conclusion (that CEO operational involvement reduces compliance risk). In practice, pharma regulatory compliance is best managed by expert compliance professionals with clear authority, adequate resources, and direct access to the CEO when genuinely needed. The CEO who stays too involved in compliance execution diverts attention from the governance-level oversight that is actually their responsibility.
This checklist helps pharma CEOs audit their current compliance delegation structure and identify the specific changes needed to maintain rigorous oversight without operational over-involvement.
Governance and Structure Checklist
Confirm that a Chief Compliance Officer or VP of Quality and Compliance holds primary compliance accountability. This person should have an organizational reporting line that ensures independence from commercial and operational pressures. They should have direct access to the CEO and to the board’s audit or governance committee. If compliance reports through Commercial or Operations without an independent escalation path, this structural problem needs correction before delegation questions can be addressed.
Verify the compliance function has adequate resources and expertise for all relevant compliance domains. Pharma compliance spans GxP quality (GMP, GCP, GLP), pharmacovigilance, regulatory submissions compliance, healthcare compliance (interactions with HCPs, promotional materials), data privacy, environmental health and safety, and import/export controls. Each of these requires specialized expertise. A compliance function that is underpowered in any domain creates risk that cannot be mitigated through CEO oversight.
Establish a Board Compliance Committee or assign compliance oversight to the Audit Committee. Board-level compliance oversight should be structured and regular, not ad hoc. The CCO should present to the board’s compliance or audit committee at least annually, and the committee should receive a compliance risk report quarterly. The CEO participates in these presentations but is not the primary presenter for compliance-specific content.
Document the CEO’s compliance responsibilities versus the CCO’s compliance responsibilities. The CEO is responsible for: setting the tone at the top for a compliance culture, ensuring adequate compliance resources, making decisions on significant compliance remediation investments, and reviewing and acting on compliance risk assessments. The CCO is responsible for: managing all compliance programs and processes, conducting and overseeing audits and inspections, responding to regulatory inquiries and observations, and leading the organization through any significant compliance events.
Quality Management System Checklist
Confirm the Quality Management System (QMS) is owned and operated by the Quality function. SOPs, change control, deviation management, CAPA, training compliance, and document management are QMS functions that should be owned by the Quality organization. The CEO should understand the QMS structure and review aggregate quality metrics, but should not be approving individual SOPs or investigating individual deviations.
Establish a quality metrics dashboard for CEO review. Key quality indicators for the CEO dashboard include: CAPA completion rate and aging, deviation trend by category and severity, audit findings by classification, inspection readiness status, and supplier quality scores. This dashboard, reviewed monthly or quarterly, provides strategic quality visibility without operational involvement.
Delegate internal audit program management to the Quality and Compliance function. Internal audits, including scheduling, conducting, reporting, and following up on audit findings, are Quality and Compliance functions. The CEO should receive the annual internal audit plan for approval and the annual internal audit summary report, but should not be managing the audit program operationally.
Regulatory Agency Interaction Checklist
Clarify the CEO’s role in FDA and EMA inspections. During a regulatory inspection, the CEO’s role is typically limited to: an opening meeting appearance to signal organizational commitment to compliance, availability for any questions the inspectors wish to direct to the CEO, and a closing meeting attendance to hear the inspectors’ verbal observations. All substantive inspection interactions should be managed by the Quality, Regulatory Affairs, and subject matter expert teams.
Establish a protocol for responding to regulatory observations and Warning Letters. Significant regulatory enforcement actions, including FDA Warning Letters, 483 observations, and consent decrees, require CEO involvement at the strategic level: approving the response strategy, committing remediation resources, and communicating with the board and investors. The detailed response development and execution belongs to the Quality and Regulatory Affairs teams, supported by outside counsel where appropriate.
Confirm that regulatory submissions (NDAs, BLAs, MAAs) are managed by Regulatory Affairs. Regulatory submissions represent the culmination of significant scientific and clinical work and should be managed by a qualified Regulatory Affairs team with appropriate scientific and clinical support. The CEO’s submission involvement should be limited to: approving the submission strategy, receiving a milestone update on submission readiness, and being briefed on the submission content for investor relations purposes.
For context on how regulatory compliance delegation connects to the broader regulatory affairs function, see pharma regulatory affairs, which provides a comprehensive framework for delegating across all regulatory functions.
Healthcare Compliance Checklist
Verify that promotional materials review and approval are managed by the Medical/Legal/Regulatory review process without CEO involvement. Promotional materials in the pharmaceutical industry require review by Medical Affairs, Legal, and Regulatory Affairs to ensure compliance with FDA promotional standards. This review process should be owned by these functions, not by the CEO or Commercial leadership. The CEO’s appropriate involvement is approving the overall promotional strategy, not reviewing individual materials.
Confirm that healthcare professional (HCP) interactions are managed within a compliance-approved framework. Interactions with HCPs, including speaker programs, advisory boards, investigator meetings, and medical education activities, must comply with regulations and industry codes. The Compliance function should own the policies and monitoring of these interactions. The CEO should be aware of the overall HCP engagement strategy and any significant compliance concerns, not the operational management of individual programs.
Establish aggregate spend reporting processes that do not require CEO involvement. Sunshine Act reporting and similar transparency requirements in other jurisdictions require systematic tracking of HCP payments and transfers of value. This should be a fully automated and managed process within Compliance and Finance, with the CEO receiving only an annual summary confirmation that reporting is complete and accurate.
Compliance Culture Checklist
Schedule an annual CEO communication on compliance culture. The CEO’s most important compliance role is tone at the top. An annual all-hands communication from the CEO specifically affirming the organization’s commitment to compliance, providing recognition for compliance achievement, and acknowledging any compliance challenges the organization is working to address is a high-impact CEO compliance activity that cannot be delegated.
Ensure the speak-up/ethics hotline has a reporting path independent of the CEO’s direct reports. Employees who witness compliance concerns must have access to a reporting mechanism that does not require going through their direct management chain. The CCO or an independent ethics hotline service should own this channel, with significant reports going to the CCO and board, not filtered through the CEO.
Review the annual compliance training completion rate in the monthly CEO dashboard. Compliance training completion is a measurable indicator of compliance culture. Including it in the CEO’s monthly dashboard, with a defined expectation (95%+ completion) and a response protocol when it falls below that threshold, is a simple and effective compliance oversight mechanism.
According to McKinsey research on pharmaceutical compliance effectiveness, the most effective pharmaceutical compliance programs are those with strong independent compliance leadership, adequate resources, and CEO-level cultural commitment, combined with minimal CEO operational involvement in compliance execution. This combination creates both compliance effectiveness and strategic executive capacity.
See pharma CEO delegation guide for a broader framework on structuring oversight across all regulated functions in pharmaceutical and biotech organizations.
Reviewing the Checklist
Each unchecked item on this list represents either a delegation gap (a compliance function the CEO is managing that should be delegated) or a governance gap (an oversight mechanism the CEO should have but does not). Prioritize the most significant gaps and assign clear responsibility for closing them, with defined timelines.
Regulatory compliance done well protects patients, preserves product approvals, and manages organizational risk. Done with the right delegation structure, it does all of this without consuming disproportionate CEO time and attention. That is the goal this checklist supports.
Related Reading
For further context, explore Delegation Checklist for Biotech CEO Clinical Operations and Delegation Checklist for Energy CEO: Capital Projects.